SARS-COV-2 IgG antibody response in pregnant women at delivery

Tsatsaris, Vassilis; Mariaggi, Alice Andrée; Launay, Odile; Couffignal, Camille; Rousseau, Jessica; Ancel, Pierre Yves; Marcault, Estelle; Ville, Y.; Cordier, Anne; Vivanti, Alexandre J.; Carrara, Julie; Luton, Dominique; Dommergues, Marc; Borie, Constance; Kayem, Gilles; Alessandrini, Vivien; Lecomte, Laurence; Meritet, Jean François; Leruez‐Ville, Marianne; Goffinet, François; Dubois, Claire M.; Picone, Olivier; Fellous, Christelle Vauloup

doi:10.1016/j.jogoh.2020.102041

Cited by 13 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La atención del parto en gestantes con Covid-19 no es diferente, algunos estudios demuestran que las probabilidades de parto prematuro aumentan en las gestantes infectadas (Mehan, Venkatesh y Girish 2020; Lu et al, 2020;López et al, 2020). El término de la gestación está más asociado a las cesáreas, el cuadro clínico ocasionado por el virus pasa rápidamente a la gravedad, por ello es mejor terminar la gestación cuando se tiene a una gestante de 34 a más semanas en condiciones de realizar un trabajo de parto; aunque existen evidencias de realizar cesáreas como método de terminación elegida Cheng et al, 2020;Tsatsaris et al, 2021).…”

Section: Vigilancia Epidemiológicaunclassified

Vigilancia epidemiológica y atención a gestantes con Covid-19 en el sistema de salud

Mujica¹,

Espinoza²,

Vega³

2022

RCS

View full text Add to dashboard Cite

gestante con Covid-19 en el sistema de salud a partir de una revisión sistemática. La metodología utilizada refiere a una revisión sistemática, enfoque cualitativo descriptivo. En los estudios analizados se tuvo un total de 1.009 gestantes con resultados 100% positivos al Sars-Cov 2 mediante prueba de PCR, de las cuales solo el 7,23% recibieron control prenatal, se halló transmisión vertical en 1,39% seguido de complicaciones obstétricas en su mayoría como la Preeclampsia, HTA gestacional, diabetes gestacional y parto pre-términos; hubo predominio de las cesáreas al 37%. La transmisión vertical ocurrió en solo 28 de un total de 1.009 RN, cuyo nexo epidemiológico se asocia al contacto directo de la madre. Se concluye que la vigilancia epidemiológica fue insuficiente a las gestantes con Covid-19; la tasa de mortalidad no fue mayor a la estimada para las no gestantes; y no hay transmisión vertical.

show abstract

Section: Vigilancia Epidemiológicaunclassified

Vigilancia epidemiológica y atención a gestantes con Covid-19 en el sistema de salud

Mujica¹,

Espinoza²,

Vega³

2022

RCS

View full text Add to dashboard Cite

show abstract

“…The serological evaluation was mainly carried out at the time of hospitalization, at the time of delivery, or randomly during pregnancy. However, to our knowledge, this is the first study assessing maternal and neonatal outcomes in a population sampled both in the first trimester and in the perinatal period [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 Seroconversion and Pregnancy Outcomes in a Population of Pregnant Women Recruited in Milan, Italy, between April 2020 and October 2020

Accurti

Gambitta

Iodice

et al. 2022

IJERPH

View full text Add to dashboard Cite

The possible link between SARS-CoV-2 infection and adverse pregnancy outcomes has so far demonstrated heterogeneous results in terms of maternal, fetal, and neonatal complications. We aim to investigate the correlation between SARS-CoV-2 seroconversion and/or neutralization titer and pregnancy outcomes. We analyzed a population of 528 pregnant women followed up from the first trimester of gestation until delivery. For each woman, we collected a first blood sample between 11 and 13 weeks of gestation and a second sample in the perinatal period (between peripartum and puerperium) to assess the presence of SARS-CoV-2 antibodies and/or microneutralization titer (MN titer). Data on pregnancy outcomes (gestational age at delivery, preterm birth before 34 weeks, hypertensive disorders, gestational diabetes, and abnormal fetal growth) were collected. We observed that serologic status per se is not associated with major pregnancy complications. On the contrary, the MN titer was associated with increased odds of gestational diabetes. Although we mainly reported asymptomatic SARS-CoV-2 infections and the absence of severe maternal and neonatal adverse outcomes, SARS-CoV-2 infection might challenge the maternal immune system and explain the moderate increase in adverse outcome odds.

show abstract

“…Eight studies investigated the seroprevalence of SARS-CoV-2 in pregnant or parturient women, reporting estimates ranging from 2.6% (95% CI 1.7% to 4%) and 14.3% between March and June 2020 (median 6.9% (IQR 5.1%-12%); n=8) [99][100][101][102][103][104][105] (online supplemental figure S2C). One study provided combined estimates of blood donors Open access and pregnant women of 14.8% in Sweden between March and December.…”

Section: Seroprevalence Estimatesmentioning

confidence: 99%

Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January–December 2020

Vaughan,

Duffell,

Freidl

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectivesSystematic review of SARS-CoV-2 seroprevalence studies undertaken in the WHO European Region to measure pre-existing and cumulative seropositivity prior to the roll out of vaccination programmes.DesignA systematic review of the literature.Data sourcesWe searched MEDLINE, EMBASE and the preprint servers MedRxiv and BioRxiv in the WHO ‘COVID-19 Global literature on coronavirus disease’ database using a predefined search strategy. Articles were supplemented with unpublished WHO-supported Unity-aligned seroprevalence studies and other studies reported directly to WHO Regional Office for Europe and European Centre for Disease Prevention and Control.Eligibility criteriaStudies published before the widespread implementation of COVID-19 vaccination programmes in January 2021 among the general population and blood donors, at national and regional levels.Data extraction and synthesisAt least two independent researchers extracted the eligible studies; a third researcher resolved any disagreements. Study risk of bias was assessed using a quality scoring system based on sample size, sampling and testing methodologies.ResultsIn total, 111 studies from 26 countries published or conducted between 1 January 2020 and 31 December 2020 across the WHO European Region were included. A significant heterogeneity in implementation was noted across the studies, with a paucity of studies from the east of the Region. Sixty-four (58%) studies were assessed to be of medium to high risk of bias. Overall, SARS-CoV-2 seropositivity prior to widespread community circulation was very low. National seroprevalence estimates after circulation started ranged from 0% to 51.3% (median 2.2% (IQR 0.7–5.2%); n=124), while subnational estimates ranged from 0% to 52% (median 5.8% (IQR 2.3%–12%); n=101), with the highest estimates in areas following widespread local transmission.ConclusionsThe low levels of SARS-CoV-2 antibody in most populations prior to the start of vaccine programmes underlines the critical importance of targeted vaccination of priority groups at risk of severe disease, while maintaining reduced levels of transmission to minimise population morbidity and mortality.

show abstract

SARS-COV-2 IgG antibody response in pregnant women at delivery

Cited by 13 publications

References 20 publications

Vigilancia epidemiológica y atención a gestantes con Covid-19 en el sistema de salud

Vigilancia epidemiológica y atención a gestantes con Covid-19 en el sistema de salud

SARS-CoV-2 Seroconversion and Pregnancy Outcomes in a Population of Pregnant Women Recruited in Milan, Italy, between April 2020 and October 2020

Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January–December 2020

Contact Info

Product

Resources

About